Holen Sie sich die Stockscreener-App
168.82
2.97%
4.87
Handel nachbörslich:
166.41
-2.41
-1.43%
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology - Zacks Investment Research
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month - Zacks Investment Research
Astrazeneca (AZN) Rises Higher Than Market: Key Facts - Zacks Investment Research
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? - Zacks Investment Research
The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk - Zacks Investment Research
Top Research Reports for Mastercard, AstraZeneca & Sandisk - Zacks Investment Research
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? - Zacks Investment Research
AstraZeneca reports HICKORY Phase III results for AstraZeneca stock - ad-hoc-news.de
AstraZeneca Summit Deal: What Does Completion Unlock? - Kalkine Media
AstraZeneca PLCAmerican Depositary Shares (NYSE:AZN) Stock Quote - FinancialContent
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint - Yahoo Finance
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual MeetingSlideshow (NYSE:AZN) 2026-10-12 - Seeking Alpha
AstraZeneca's efzimfotase alfa adult data point to $4.4bn peak sales potential, says Citi - Proactive financial news
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal - Benzinga
AstraZeneca pins bone disease drug’s Phase III failure on high placebo response - Clinical Trials Arena
Weekly Recap: U.S. $50B expansion and Summit stake funding ivonescimab - TradingView
AstraZeneca PLC (AZN) stock price, news, quote and history - Yahoo Finance Australia
ASTRAZENECA PLC CEDEAR EA RE 0. (AZND.BA) Q1 FY2026 earnings call transcript - Yahoo Finance
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth? - Yahoo Finance
AstraZeneca falls Thursday, underperforms market - MarketWatch
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results - Zacks Investment Research
Form 4 ASTRAZENECA PLC For: 8 October By Investing.com - Investing.com UK
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? - Zacks Investment Research
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
AstraZeneca (LSE:AZN) Opened A $1 Billion R&D Center In Kendall Square - Yahoo Finance
Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results - Proactive financial news
AstraZeneca PLC : Buy rating from Berenberg - www.marketscreener.com
US bank expects AstraZeneca to beat third-quarter forecasts as path clears to key lung cancer data - Proactive Investors
AstraZeneca PLC : Jefferies gives a Buy rating - www.marketscreener.com
AstraZeneca PLC : Bernstein reaffirms its Buy rating - www.marketscreener.com
AstraZeneca Takes Drug-Pricing Law Challenge To 4th Circ. - Law360
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
AstraZeneca’s Real World COPD Study in Russia Signals Strategic Respiratory Focus - TipRanks
AstraZeneca advances Tuesday, outperforms market - MarketWatch
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? - Zacks Investment Research
Citi raises AstraZeneca target to £186 as tozorakimab prospects improve - Proactive financial news
AstraZeneca opens new R&D centre in Cambridge, US - Pharmaceutical Technology
AstraZeneca Invests Over $1bn in Massachusetts - marketscreener.com
AstraZeneca Launches Research, Development Center in US - marketscreener.com
‘We’re here at the party now:’ AstraZeneca opens new Kendall hub with big hiring plans - The Business Journals
AstraZeneca CEO Soriot says drugmaker can grow without big acquisition - Seeking Alpha
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment - CNBC
AstraZeneca to invest over $1 billion in Massachusetts, boost workforce - marketscreener.com
AstraZeneca to invest over $1B in Massachusetts ops - Breakingthenews.net
A Massachusetts investment will expand AstraZeneca’s state workforce by over 50% in coming years. - Stock Titan
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts - Financial Times
AstraZeneca PLC (ZEG.DE) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
3.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):